Cargando…

MALP-2 pre-treatment modulates systemic inflammation in hemorrhagic shock

BACKGROUND: TLR-2 is expressed on the surface of leucocytes, lung and liver tissue and initiates the activation of immune response after interaction with components of the bacterial cell wall. In this experiment we investigated whether immunostimulation with TLR-2 agonists under conditions of steril...

Descripción completa

Detalles Bibliográficos
Autores principales: Pfeifer, Roman, Tschernig, Thomas, Lichte, Philipp, Dombroski, Derek, Kobbe, Philipp, Pape, Hans-Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3640975/
https://www.ncbi.nlm.nih.gov/pubmed/23587413
http://dx.doi.org/10.1186/1476-9255-10-17
_version_ 1782267958338256896
author Pfeifer, Roman
Tschernig, Thomas
Lichte, Philipp
Dombroski, Derek
Kobbe, Philipp
Pape, Hans-Christoph
author_facet Pfeifer, Roman
Tschernig, Thomas
Lichte, Philipp
Dombroski, Derek
Kobbe, Philipp
Pape, Hans-Christoph
author_sort Pfeifer, Roman
collection PubMed
description BACKGROUND: TLR-2 is expressed on the surface of leucocytes, lung and liver tissue and initiates the activation of immune response after interaction with components of the bacterial cell wall. In this experiment we investigated whether immunostimulation with TLR-2 agonists under conditions of sterile inflammation (hemorrhagic shock (HS)) may affect the immune response and remote organ inflammation. METHODS: Male C57/BL6 mice were subjected to standardized pressure-controlled HS (MAP of 35 mmHg for 90 minutes). The TLR-2 agonist macrophage-activated lipopeptide-2 (MALP-2) was administered (i.p.) either 12 hours prior to the induction of HS (Group MALP PT) or after the hypotensive period (90 minutes) (Group MALP T). After six hours, plasma cytokine levels (IL-6, KC, IL-10, and MCP-1) and lung and liver MPO activity were assessed. RESULTS: Pre-treatment with MALP-2 resulted in a significant attenuation of the systemic pro-inflammatory (IL-6) response (MALP PT: 0.83±0.2 ng/ml vs. MALP T: 1.7±0.09 ng/ml) (p<0.05). In comparison to the liver MPO activity, lung MPO levels in in group MALP PT did not show differences to levels measured in MALP T mice (1.200±200 ng/mg vs. 1.800±200 ng/mg). CONCLUSIONS: After initial inflammation, MALP-2 pre-treatment was associated with attenuated systemic immune response after sterile stimulus. The TLR-2 agonist appears to affect sterile inflammation pathways. The exact mechanisms should be studied further to better understand these affects.
format Online
Article
Text
id pubmed-3640975
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-36409752013-05-02 MALP-2 pre-treatment modulates systemic inflammation in hemorrhagic shock Pfeifer, Roman Tschernig, Thomas Lichte, Philipp Dombroski, Derek Kobbe, Philipp Pape, Hans-Christoph J Inflamm (Lond) Research BACKGROUND: TLR-2 is expressed on the surface of leucocytes, lung and liver tissue and initiates the activation of immune response after interaction with components of the bacterial cell wall. In this experiment we investigated whether immunostimulation with TLR-2 agonists under conditions of sterile inflammation (hemorrhagic shock (HS)) may affect the immune response and remote organ inflammation. METHODS: Male C57/BL6 mice were subjected to standardized pressure-controlled HS (MAP of 35 mmHg for 90 minutes). The TLR-2 agonist macrophage-activated lipopeptide-2 (MALP-2) was administered (i.p.) either 12 hours prior to the induction of HS (Group MALP PT) or after the hypotensive period (90 minutes) (Group MALP T). After six hours, plasma cytokine levels (IL-6, KC, IL-10, and MCP-1) and lung and liver MPO activity were assessed. RESULTS: Pre-treatment with MALP-2 resulted in a significant attenuation of the systemic pro-inflammatory (IL-6) response (MALP PT: 0.83±0.2 ng/ml vs. MALP T: 1.7±0.09 ng/ml) (p<0.05). In comparison to the liver MPO activity, lung MPO levels in in group MALP PT did not show differences to levels measured in MALP T mice (1.200±200 ng/mg vs. 1.800±200 ng/mg). CONCLUSIONS: After initial inflammation, MALP-2 pre-treatment was associated with attenuated systemic immune response after sterile stimulus. The TLR-2 agonist appears to affect sterile inflammation pathways. The exact mechanisms should be studied further to better understand these affects. BioMed Central 2013-04-12 /pmc/articles/PMC3640975/ /pubmed/23587413 http://dx.doi.org/10.1186/1476-9255-10-17 Text en Copyright © 2013 Pfeifer et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Pfeifer, Roman
Tschernig, Thomas
Lichte, Philipp
Dombroski, Derek
Kobbe, Philipp
Pape, Hans-Christoph
MALP-2 pre-treatment modulates systemic inflammation in hemorrhagic shock
title MALP-2 pre-treatment modulates systemic inflammation in hemorrhagic shock
title_full MALP-2 pre-treatment modulates systemic inflammation in hemorrhagic shock
title_fullStr MALP-2 pre-treatment modulates systemic inflammation in hemorrhagic shock
title_full_unstemmed MALP-2 pre-treatment modulates systemic inflammation in hemorrhagic shock
title_short MALP-2 pre-treatment modulates systemic inflammation in hemorrhagic shock
title_sort malp-2 pre-treatment modulates systemic inflammation in hemorrhagic shock
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3640975/
https://www.ncbi.nlm.nih.gov/pubmed/23587413
http://dx.doi.org/10.1186/1476-9255-10-17
work_keys_str_mv AT pfeiferroman malp2pretreatmentmodulatessystemicinflammationinhemorrhagicshock
AT tschernigthomas malp2pretreatmentmodulatessystemicinflammationinhemorrhagicshock
AT lichtephilipp malp2pretreatmentmodulatessystemicinflammationinhemorrhagicshock
AT dombroskiderek malp2pretreatmentmodulatessystemicinflammationinhemorrhagicshock
AT kobbephilipp malp2pretreatmentmodulatessystemicinflammationinhemorrhagicshock
AT papehanschristoph malp2pretreatmentmodulatessystemicinflammationinhemorrhagicshock